Overall rank by patents
#2,522
of 49,997 tracked assignees
USPTO PatentsView assignee record - 154 granted patents across 19 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Cancer ranks #2,522 of 49,997 tracked US assignees by granted-patent volume, with 154 patents across 19 technology areas.
USPTO PatentsView assignee plate
Corpus R2522 · Foreign Corporation #2,522 · 154 grants
GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL
Nearest grant-volume peer: Atlassian, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Arrowhead Pharmaceut… · near
49 score
Medela Holding · near
49 score
Quarkstar · near
49 score
Cancer Research… · this assignee
49 score
Cortica · near
49 score
3D Lighting… · lowest
7 score
What this shows Cancer's Innovation Score is 48.8/100 (top 16% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Cancer Research Technology Limited is a focused PatentsView assignee: 19 CPC subclasses with 93.5% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2019 (25 grants) versus a trough of 9 in 2015. By volume, Cancer sits between Tenneco GmbH and Lyten, Inc..
From 2019–2021 to 2022–2024, Cancer Research Technology Limited moved from 56 to 41 grants (0.73x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,044. See the growth leaderboard.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Tenneco GmbH
155 patents
Wilson Sporting Goods Co.
155 patents
Atlassian, Inc.
154 patents
CMR Surgical Limited
154 patents
Citizen Holdings Co., Ltd.
154 patents
HannStar Display Corporation
154 patents
Lumens Co., Ltd.
154 patents
Lyten, Inc.
154 patents
Cancer Research Technology Limited
154 patents
What this shows Cancer holds 154 patents at rank #2,523, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #2,523 in granted patent volume.
Other assignees with the most granted patents in Cancer's primary technology class.
Two PlainPatent-derived peer sets for Cancer, neither rank-band nor same-CPC leaders (those blocks stay above).
Nearest assignees by Innovation Score (49 here).
Nearest assignees by average claims per patent (18.4 here).
Cancer's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
49 Top 16% higher than 84% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 9 | 5.8% |
| 2016 | 13 | 8.4% |
| 2017 | 18 | 11.7% |
| 2018 | 15 | 9.7% |
| 2019 | 25 | 16.2% |
| 2020 | 13 | 8.4% |
| 2021 | 18 | 11.7% |
| 2022 | 9 | 5.8% |
| 2023 | 20 | 13.0% |
| 2024 | 12 | 7.8% |
| 2025partial year | 2 | 1.3% |
Top 15 of 19 technology areas
Overall rank by patents
#2,522
of 49,997 tracked assignees
48.8 out of 100
What to do with this data
Cancer Research Technology Limited's patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.